There is much clinical evidence for the use of ivabradine to address unmet needs in the management of systolic heart failure, in which it improve symptoms, improves quality of life, prevents hospitalization, and prolongs survival.

By contrast with other treatments in heart failure, ivabradine has a significant effect on pump failure death, which was significantly reduced by 26 % in a large-scale randomized controlled trial, but no effect on sudden cardiac death.

Ivabradine has also been demonstrated to have a beneficial effect on hospital admission for heart failure, which is an important marker of prognosis and remains a major objective to reduce healthcare costs.